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A direct interaction between the adaptor protein Cbl-b and the
kinase Zap-70 induces a positive signal in T cells 
Zhihong Zhang, Chris Elly, Ling Qiu, Amnon Altman and Yun-Cai Liu
Engagement of the T-cell receptor (TCR)–CD3 complex
induces a rapid increase in the activities of Src-family
and Syk/Zap-70-family kinases [1,2]. These activated
kinases then induce the tyrosine phosphorylation of
multiple intracellular proteins, eventually leading to
T-cell activation. One of the prominent substrates for
these kinases is the adaptor protein Cbl [3] and recent
studies suggest that Cbl negatively regulates upstream
kinases such as Syk and Zap-70 [4,5]. Cbl-b, a
homologue of Cbl, is widely expressed in many tissues
and cells including hematopoietic cells [6,7]. Cbl-b
undergoes rapid tyrosine phosphorylation upon
stimulation of the TCR and cytokine receptors [8,9]. The
role of Cbl-b is unclear, however. Here, we show that
overexpression of Cbl-b in T cells induced the
constitutive activation of the transcription factor
nuclear factor of activated T cells (NFAT). A loss-of-
function mutation in Cbl-b disrupted the interaction
between Cbl-b and Zap-70 and nearly completely
abrogated the Cbl-b-mediated activation of NFAT.
Unlike the proposed role of Cbl as a negative regulator,
our results suggest that the Cbl homologue Cbl-b has a
positive role in T-cell signaling, most likely via a direct
interaction with the upstream kinase Zap-70.
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Results and discussion
To begin to understand the functional involvement of
Cbl-b in T-cell signaling, we assessed the effect of tran-
siently overexpressed Cbl-b on transactivation of a
luciferase reporter gene driven by NFAT-binding sites
(NFAT–luc). This NFAT transcriptional unit is derived
from the interleukin-2 (IL-2) gene [10,11] and has been
widely used as an indicator for T-cell activation. Lysates of
human leukemic Jurkat T cells expressing SV40 large T
antigen (Jurkat-TAg cells) that had been transiently trans-
fected with either empty vector or a plasmid encoding
Cbl-b together with the NFAT–luc reporter plasmid were
assayed for luciferase activity under different stimulation
conditions. Overexpression of Cbl-b induced NFAT activa-
tion under resting conditions and this was enhanced upon
stimulation with anti-CD3 antibody (Figure 1a). A synergy
between Cbl-b and a TCR-mediated signal was observed
for the induction of NFAT activation when different
amounts of anti-CD3 antibody were used for stimulation
(Figure 1b). In contrast, overexpression of Cbl inhibited
both basal and anti-CD3-stimulated NFAT activation
under the same conditions. Normalization of the luciferase
activity from the reporter in these experiments relative to
the maximal luciferase activity induced by phorbol myris-
tate acetate (PMA) and ionomycin or to a reference β-galac-
tosidase activity showed similar results (see Supplementary
material published with this paper on the internet). The
level of Cbl-b-mediated activation of NFAT correlated
with its protein expression level, as shown by titration of
the plasmid amounts for transfection. Even low levels of
Cbl-b induced activation of NFAT under basal and anti-
CD3-stimulated conditions (Figure 1c).
Recent studies suggest that Cbl-family proteins participate
in the regulation of the protein tyrosine kinases with which
they associate [4]. We recently demonstrated that Cbl-b
binds Syk and that a loss-of-function mutation (a glycine to
glutamic acid substitution at position 298, G298E) in Cbl-b
disrupts its interaction with Syk [9]. We then analyzed the
effect of the G298E mutation on NFAT activation. Over-
expression of the G298E Cbl-b mutant completely abol-
ished Cbl-b-induced NFAT activation under basal and
ionomycin-stimulated conditions (Figure 2a). A large
reduction in NFAT activity induced by this mutant com-
pared with that induced by wild-type Cbl-b was observed
under anti-CD3-stimulated conditions. 
To further confirm that the G298E mutation in Cbl-b
achieved its effect by disrupting the interaction between
Cbl-b and Zap-70, we then examined the molecular basis
of Cbl-b–Zap-70 binding. Coexpression of Cbl-b with
Zap-70 caused basal-level tyrosine phosphorylation of
Cbl-b, which was increased upon anti-CD3-stimulation
(Figure 2b). In contrast, the G298E Cbl-b mutant was not
tyrosine phosphorylated under resting conditions. Anti-
CD3 stimulation induced only a low level of tyrosine
phosphorylation of this mutant. Zap-70 coimmunoprecipi-
tated with Cbl-b, and this interaction was enhanced by
anti-CD3 stimulation. A markedly reduced amount of
Zap-70 coimmunoprecipitated with the G298E Cbl-b
mutant, however (Figure 2b). 
Both Cbl and Cbl-b interact with Tyr316 of Syk [9,12],
suggesting that these two molecules bind to the same site
in Syk. As Cbl binds to the corresponding tyrosine residue
of Zap-70 (Tyr292) [13], we then examined whether
Tyr292 in Zap-70 was also required for the interaction
with Cbl-b. To this end, Jurkat-TAg cells were trans-
fected with plasmids expressing wild-type Zap-70 or a
Zap-70 mutant containing a tyrosine to phenylalanine sub-
stitution at position 292 (Y292F) together with a plasmid
encoding Cbl-b. Consistent with the data in Figure 2b,
Zap-70 was coimmunoprecipitated from cells expressing
wild-type Zap-70 and Cbl-b (Figure 2c). A markedly
reduced amount of the Y292F Zap-70 mutant coimmuno-
precipitated with Cbl-b under both resting and OKT3-
stimulated conditions, however.
We recently showed that Syk binds to the amino-terminal
phosphotyrosine-binding (PTB)-like domain of Cbl-b [9].
To assess whether this is also true for the Zap-70–Cbl-b
interaction, Jurkat-TAg cells were cotransfected with a
plasmid encoding Zap-70 together with a plasmid encoding
the amino-terminal 349 amino acids of Cbl-b, Cbl-b(N), or
a mutant form of this fragment containing the G298E
mutation. Cell lysates were immunoprecipitated with anti-
Cbl-b antibody and then immunoblotted with anti-phos-
photyrosine antibody. As demonstrated for full-length
Cbl-b and the G298E Cbl-b mutant (Figure 2b), the form
of Cbl-b(N) containing the G298E mutation did not inter-
act with Zap-70 (Figure 2d), indicating that the observed
Zap-70–Cbl-b interaction is mediated via the amino-
terminal portion of Cbl-b. 
The similar interaction between full-length Cbl-b or
Cbl-b(N) and Zap-70 prompted us to assess a functional
role for Cbl-b(N) in NFAT activation. Unlike full-length
Cbl-b, Cbl-b(N) did not induce NFAT activation under
resting conditions (Figure 3a), and in fact decreased
NFAT activation under anti-CD3-stimulated conditions.
This result implies that, by binding to Zap-70, Cbl-b(N)
may play a dominant-negative role in events downstream
of Cbl-b. To test this hypothesis, we cotransfected a
plasmid encoding Cbl-b with plasmids encoding Cbl-b(N)
or the G298E Cbl-b(N) mutant and the NFAT–luc
reporter plasmid, and assessed their respective effects on
NFAT activation. As shown in Figure 3b, coexpression of
Cbl-b with Cbl-b(N) inhibited Cbl-b-induced NFAT acti-
vation. This inhibitory effect was largely rescued by coex-
pression of the G298E Cbl-b(N) mutant. Titration of the
plasmid amounts showed that even as little as 0.5 µg 
Cbl-b(N) plasmid (that is, a Cbl-b(N) : Cbl-b ratio of 1:4)
displayed an inhibitory effect on Cbl-b-mediated NFAT
activation. This result suggests that Cbl-b(N) exerts its
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Figure 1
Effect of Cbl-b on NFAT induction in Jurkat T cells. (a) Jurkat-TAg cells
were transfected with empty vector (pEF) or a plasmid encoding
hemagglutinin (HA)-tagged full-length Cbl-b (5 µg each) plus 5 µg
NFAT–luc reporter plasmid. At 24 h after transfection, cells were either
left unstimulated (control), or stimulated with anti-CD3 (OKT3) ascites
(1:500), or with ionomycin (iono; 100 ng/ml) for 6–10 h. Cells were
then lysed and the luciferase activity was determined as described
previously and expressed in arbitrary units (AU) [17]. (b) Cells were
transfected with empty vector (control), plasmids encoding Cbl-b or
Cbl (5 µg each) plus 5 µg NFAT–luc reporter plasmid. At 24 h after
transfection, cells were either left unstimulated or stimulated with
different amounts of anti-CD3 antibody (OKT3; µl) at a dilution of 1:10
for 6–10 h. Lysates were then assayed for luciferase activity. (c) Jurkat-
TAg cells were transfected with different amounts of plasmid encoding
HA-tagged Cbl-b plus an equal amount of NFAT–luc reporter gene (5
µg in each case). The total amounts of plasmids used for each
transfection were adjusted to the same final amount by addition of
empty vector where necessary. At 24 h after transfection, cells were
either left unstimulated (control), or stimulated with anti-CD3 (OKT3)
ascites (1:500), or with ionomycin (iono; 100 ng/ml) for 6–10 h. The
luciferase activity induced by PMA plus ionomycin was similar among
all the groups (data not shown). The insert shows aliquots of cell
lysates from each transfection experiment immunoblotted with anti-HA
antibody to detect the levels of Cbl-b protein. The results shown in
(a–c) are representative of at least six separate experiments. Bars
represent the means of triplicate samples. Standard deviations are
depicted by error bars.
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dominant-negative role by a direct, competitive inter-
action with Zap-70. 
In summary, we demonstrate that overexpression of Cbl-
b induces the constitutive transactivation of NFAT,
which is further enhanced by anti-CD3 stimulation. This
effect is mediated by a direct interaction between the
Cbl-b PTB domain and the Tyr292 residue of Zap-70, as
a loss-of-function mutation (G298E) in Cbl-b disrupted
its interaction with Zap-70 and abolished Cbl-b-induced
NFAT activation. 
Accumulating evidence suggests that Cbl is a negative
regulator of intracellular signaling: Cbl-deficient mice
display lymphoid hyperplasia, and thymocytes from these
mice exhibit elevated levels of Zap-70 kinase activity [5];
Cbl directly inhibits the kinase activity of Syk [4], and the
TCR-induced activation of NFAT (Figure 1) and AP-1
[14]; and Cbl is involved in the hyporesponsiveness of
anergic T cells [15]. Although the Cbl–Grb2 interaction
[14] or the Cbl–Crk-L–Rap-1 signaling pathway [15] are
thought to be responsible for the negative role of Cbl, a
direct interaction between Cbl and Zap-70 [5] and/or Syk
[4] most likely accounts for the inhibitory function of Cbl.
In contrast, we show here that Cbl-b positively regulates
T-cell signaling leading to NFAT activation, and that this
is mediated by a direct interaction between Cbl-b and the
Tyr292 residue of Zap-70. These results suggest that by
binding to the same phosphorylated tyrosine residue of
Zap-70, Cbl or Cbl-b can induce either a negative (for
Cbl) or a positive (for Cbl-b) signal via Zap-70. Consider-
ing the critical role of Syk/Zap-70-family protein tyrosine
Brief Communication 205
Figure 2
Effect of the G298E mutation in Cbl-b on
Cbl-b-mediated NFAT activation and on the
interaction between Cbl-b and Zap-70.
(a) Jurkat-TAg cells were transfected with the
NFAT–luc reporter plasmid (5 µg) plus either
empty vector (pEF), or plasmids encoding HA-
tagged Cbl-b or G298E Cbl-b mutant
(G298E; 5 µg each). At 24 h after transfection,
cells were either left unstimulated (control), or
stimulated with anti-CD3 (OKT3) ascites
(1:500), or with ionomycin (iono; 100 ng/ml)
for 6–10 h. Cell lysates were analyzed for
luciferase activity. Bars represent the mean of
triplicate samples. The data shown are
representative of three independent
experiments. Aliquots of cell lysates were
analyzed with anti-HA antibody to detect levels
of Cbl-b expression (insert). (b) Jurkat-TAg
cells were transfected with plasmid containing
Zap-70 (2 µg) together with plasmid
containing Cbl-b or G298E Cbl-b (5 µg each).
At 24 h after transfection, lysates were
prepared from unstimulated (–) or anti-CD3-
stimulated (+; 5 min) cells, immunoprecipitated
with anti-Cbl-b antibody, and immunoblotted
with anti-phosphotyrosine antibody (anti-PTyr),
according to our published protocol [18]. The
positions of Cbl-b and Zap-70 are indicated by
arrows. The membrane was reprobed with
anti-Zap-70 antibody (middle panel), then with
anti-Cbl-b antibody (lower panel). (c) Jurkat-
TAg cells were transfected with plasmid
encoding Cbl-b together with plasmid
containing Zap-70 or the Y292F Zap-70
mutant (Y292F). Cell lysates prepared as in (b)
were immunoprecipitated with anti-Cbl-b
antibody and immunoblotted with anti-
phosphotyrosine antibody (upper panel). The
position of Zap-70 is indicated by an arrow.
The membrane was reprobed with anti-Zap-70
antibody (middle panel), then with anti-Cbl-b
antibody (lower panel). (d) Jurkat-TAg cells
were transfected with Zap-70 plasmid (2 µg)
plus empty vector, and a plasmid containing an
HA-tagged form of the amino-terminal region
of Cbl-b (Cbl-b(N)), or a loss-of-function
mutant of this fragment (G298E(N); 5 µg
each). At 24 h after transfection, lysates were
prepared from resting (–) or anti-CD3-
stimulated (+; 5 min) cells, immunoprecipitated
with anti-HA antibody and immunoblotted with
anti-phosphotyrosine antibody (upper panel).
The position of Zap-70 is indicated by an
arrow. The same membrane was reprobed
with anti-Zap-70 antibody (middle panel), then
with anti-HA antibody (lower panel). The
position of Cbl-b(N) is indicated by the arrow.
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kinases in lymphocyte development and activation [16], it
can be envisioned that a delicate functional balance
between Cbl and Cbl-b may have a significant impact on
these kinase-mediated immune responses. 
Supplementary material
Additional data on the specificity of Cbl-b in NFAT activation and addi-
tional methodological detail are published with this paper on the internet.
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Figure 3
Effect of Cbl-b(N) on Cbl-b-induced NFAT activation. (a) Jurkat-TAg
cells were transfected with the NFAT–luc reporter plasmid (5 µg)
together with empty vector (pEF), or plasmids expressing full-length
Cbl-b or Cbl-b(N) (5 µg each). At 24 h after transfection, cells were left
unstimulated (control) or stimulated with anti-CD3 antibody (OKT3) or
ionomycin (iono), as indicated, for 6–10 h. Cell lysates were analyzed
for luciferase activity. Total amounts of plasmids were adjusted to 15 µg
with empty vector. (b) Jurkat-TAg cells were transfected with a plasmid
encoding Cbl-b (5 µg) together with empty vector (pEF), or plasmids
encoding Cbl-b(N) or the G298E Cbl-b(N) mutant (G298E(N); 5 µg
each) plus 5 µg NFAT–luc reporter plasmid. At 24 h after transfection,
cells were either left unstimulated (control) or stimulated, as indicated,
for 6–10 h and then assayed for luciferase activity. (c) Jurkat-TAg cells
were transfected with plasmid encoding Cbl-b plus NFAT–luc reporter
plasmid together with different amounts of Cbl-b(N) as indicated. At
24 h after transfection, cells were either left unstimulated (control) or
stimulated with anti-CD3 (OKT3) ascites (1:500) for 6–10 h. Aliquots of
cell lysates were analyzed with anti-HA antibody (insert) to detect
protein levels of wild-type Cbl-b and Cbl-b(N). The data in (a–c) are
representative of three independent experiments.
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Supplementary results
To ensure that the observed NFAT activation by Cbl-b was
not a non-specific effect due to Cbl-b overexpression, we
normalized the luciferase activity in relation to that induced
by a combination of PMA and ionomycin stimulation.
Under our experimental conditions, the maximal luciferase
activity induced by PMA and ionomycin was normally about
five times higher than that induced by anti-CD3 stimulation
and no significant difference among different transfections
was observed. As shown in Figure S1a, a similar pattern of
the relative luciferase activity was observed, when normal-
ized to the luciferase activity induced by PMA and iono-
mycin. As a further control, we cotransfected a plasmid
containing β-galactosidase and the NFAT–luc reporter
plasmid and empty vector or Cbl-b plasmid. When the
luciferase activity was normalized to β-galactosidase activity,
Cbl-b also induced a high level of NFAT activation under
resting conditions that was enhanced by anti-CD3 stimula-
tion (Figure S1b). It should be mentioned that coexpression
with β-galactosidase caused a marked reduction in NFAT
activity (~80%) (compare Figure S1b with Figure 1a), proba-
bly due to the interference of the β-galactosidase enzyme.
Due to the similarity of all three methods, in the following
experiments we adopted a simple method as in Figure 1a to
present our luciferase data. 
The IL-2-gene-derived NFAT transcriptional unit used in
this study contains a binding site for the NFAT transcrip-
tion factor and a binding site for AP-1 [S1,S2]. The inte-
gration of a Ca2+-dependent and a Ras-dependent signal
induces the transactivation of the promoter of the NFAT
gene [S3–S5]. Next, we examined whether blockage of
one of the two signals has any effect on Cbl-b-induced
NFAT activation. As shown in Figure S2a, pretreatment
of transfected cells with cyclosporin A (CsA), an inhibitor
of calcineurin, reduced Cbl-b-induced NFAT activation
under both basal and anti-CD3-stimulated conditions.
Similarly, coexpression of a dominant-negative version of
Ras, RasN17, almost completely abolished Cbl-b-induced
NFAT activation under either resting or anti-CD3-stimu-
lated conditions (Figure S2b). This effect of RasN17 did
not reflect a non-specific inhibition of Cbl-b protein
expression, as equivalent amounts of Cbl-b proteins were
detected in the samples cotransfected with either the
empty vector or plasmid encoding RasN17 (Figure S2c). 
Supplementary discussion
In the present study, we have demonstrated that overex-
pression of Cbl-b induced constitutive transactivation of
NFAT, which was enhanced by anti-CD3 stimulation.
This Cbl-b-mediated effect requires a Ca2+ signal and
functional Ras, implying that the target of Cbl-b lies
upstream of TCR-mediated signaling pathways. We
Supplementary material
Figure S1
Effects of Cbl-b on NFAT induction in Jurkat T cells. (a) Jurkat-TAg
cells were transfected with empty vector (pEF) or plasmids encoding
HA-tagged full-length Cbl-b (5 µg each) plus 5 µg NFAT–luc reporter
plasmid. At 24 h after transfection, cells were left unstimulated
(control), or stimulated with anti-CD3 (OKT3) ascites (1:500),
ionomycin (iono; 100 ng/ml), or PMA (50 ng/ml) plus ionomycin
(100 ng/ml) for 6–10 h. Cells were then lysed and the luciferase
activity was determined. The relative luciferase activity was converted
in relation to the maximal activity induced by PMA plus ionomycin.
(b) Cells were transfected as in (a) but with an additional reference
reporter plasmid encoding β-galactosidase (3 µg). The relative
luciferase activity was represented relative to β-galactosidase
enzymatic activity. Bars represent the mean of triplicate samples.
Standard deviations are depicted by error bars. The results shown in
(a) are representative of three separate experiments.
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further demonstrated that this effect was mediated by the
direct interaction between the Cbl-b PTB domain and the
Tyr292 residue of Zap-70, as a loss-of-function mutation
(G298E) in Cbl-b disrupted its interaction with Zap-70
and abolished Cbl-b-induced NFAT activation. Our
results clearly indicate that Cbl-b plays a positive role in
T-cell signaling, which leads to NFAT activation.
Two recent studies indicate that the Tyr292 residue of
Zap-70 is a negative regulatory site: a Y292F Zap-70
mutant exhibits constitutive activation towards NFAT
activation [S6,S7]. We recently observed the same result
with a corresponding Syk Y316F mutant (our unpublished
observations). Taken together, these results seem to agree
with a hypothesis that these sites interact with a negative
regulatory molecule(s). Thus, our data on Cbl-b as shown
in the present study disagree with this model regarding
the regulation of Syk/Zap-70. It is also shown, however,
that Tyr292 is located in the linker region encompassing a
negative regulatory domain, which contains binding sites
for critically positive signaling molecules such as Vav [S8].
Removal of this linker region results in a Zap-70 mutant
that is constitutively active [S7]. Thus, it is possible that
the Y292F mutation of Zap-70 (or Y316F of Syk) may
acquire a gain-of-function property via a structural change
of this linker region, in addition to the disruption of its
interaction with Cbl or Cbl-b. Clearly, future studies are
needed to dissect the exact role of these binding sites for
Cbl-family proteins in Zap-70 and Syk.
Our hypothesis that binding to Tyr292 of Zap-70 trans-
duces either a positive and a negative signal is supported
by the observation that Cbl-b(N), while still retaining the
ability to bind Zap-70, does not induce constitutive activa-
tion of NFAT. Rather, it functions as a dominant-negative
regulator of Cbl-b-induced NFAT activation. In addition,
this inhibitory effect of Cbl-b(N) is markedly alleviated by
the G298E mutation, suggesting that a direct interaction
with Zap-70 accounts for the inhibitory function of
Cbl-b(N). Consistent with this observation is our previous
work on a Cbl-b fragment corresponding to Cbl-b(N),
v-Cbl, which also interacts with Zap-70 [S9], but is unable
to induce NFAT activation under either resting or iono-
mycin-stimulated conditions [S10]. 
The constitutive activation of NFAT by Cbl-b is reminis-
cent of an oncogenic Cbl mutant (70Z), which also causes
constitutive NFAT activation [S10]. Both proteins require
a Ca2+ signal and functional Ras to exert their effects,
implying that their targets of action are upstream of these
two signals. Indeed, we recently demonstrated that a
similar loss-of-function mutation in 70Z has the same
effect as Cbl-b G298E on NFAT activation, suggesting
these two molecules employ a common mechanism, that
is, direct targeting of their upstream binding protein
Zap-70. One obvious difference between these two mole-
cules is that 70Z but not Cbl-b synergizes with ionomycin
treatment [S10] (Figure 1). Another difference is that
while Cbl-b enhances anti-CD3-induced NFAT activa-
tion, 70Z inhibits this event [S11]. Although the exact
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Figure S2
Effects of cyclosporin A and a dominant-negative Ras on Cbl-b-
induced NFAT activation. (a) Jurkat-TAg cells were transfected with
empty vector (pEF) or plasmid encoding Cbl-b (5 µg each) plus
NFAT–luc reporter plasmid. Cells were left untreated or treated with
cyclosporin A (CsA, 50 ng/ml) for 10 min before treatment with or
without anti-CD3 (OKT3) ascites (1:500), or ionomycin (iono;
100 ng/ml) for another 8—10 h. Luciferase activity was then
determined. (b) Jurkat-TAg cells transfected with NFAT–luc reporter
plasmid (5 µg) and either empty vector (pEF) or plasmid containing
Cbl-b (5 µg each) plus a plasmid encoding dominant-negative Ras
(RasN17) or a corresponding empty vector (pcDNA3; 5 µg each) were
left unstimulated (control) or stimulated with anti-CD3 (OKT3), or
ionomycin for 8–10 h as in (a). Cell lysates were analyzed for luciferase
activity. Bars represent the mean of triplicate samples. The data shown
(a,b) are representative of three independent experiments. (c) Aliquots
of cell lysates in (b) were analyzed with anti-HA or anti-Ras antibody.
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mechanism underlying these different effects remains to
be explored, differential complex formations by these two
molecules may explain the observed functional differ-
ences. Nevertheless, these functional differences agree
with our model that interaction of the same Tyr292
residue in Zap-70 by different Cbl-family proteins can
result in differential Zap-70-mediated signaling. 
The endogenous expression of Cbl-b in T cells and other
hematopoietic cells and its rapid tyrosine phosphorylation
upon stimulation of TCR and other cytokine receptors
[S12,S13] strongly suggest that Cbl-b is involved in
antigen- or cytokine-receptor-mediated signaling. In the
present study, we demonstrated that anti-CD3 stimulation
enhances Cbl-b-induced NFAT activation. Titration
experiments using different amounts of either Cbl-b
plasmid for transfection or different amounts of anti-CD3
antibody for stimulation showed that a synergy between
Cbl-b and TCR ligation does exist in the induction of
NFAT activation, suggesting a direct connection between
Cbl-b and TCR-mediated signaling. The failure to see a
strong synergy between these two signals in some other
experiments could suggest that Cbl-b is not a limiting
factor in this process. Otherwise, tyrosine phosphorylation
of Cbl-b induced by TCR ligation recruits Crk-L [S12].
Recently, a Cbl–Crk-L–Rap1 signal has been proposed to
be responsible for T-cell anergy [S14]. It can be specu-
lated that under anti-CD3-stimulated conditions, Cbl-b
can also transduce a negative signal(s). A functional
balance between positive and negative signals will deter-
mine the effect of Cbl-b on NFAT activation under anti-
CD3-stimulated conditions. Other critical signaling
molecules in T-cell activation such as Syk (Figure S3) or
LAT [S15] do not synergize with TCR ligation either. 
The functional implication of Cbl family proteins in the
regulation of receptor-mediated signaling is further compli-
cated by several other studies showing that Cbl, a negative
regulator, also functions as a positive regulator of intracel-
lular signal transduction: Cbl was reported to positively
regulate a Src-mediated signaling pathway leading to bone
resorption [S16], IL-4-induced cell proliferation [S17] or
integrin-mediated cell spreading or cell adhesion
[S18,S19], in addition to its attributed role as a negative
regulator. Similarly, it was reported that Cbl-b binds Vav
and inhibits Vav-mediated activation of Jun N-terminal
kinase [S20,S21], although we do not observe a Cbl-b–Vav
interaction in Jurkat T cells even when both Cbl-b and Vav
are overexpressed [S12]. At present, the exact mechanism
for the dual function of Cbl and/or Cbl-b remains unclear.
These findings suggest, however, that both Cbl and/or
Cbl-b can function as positive or negative regulators,
depending on the specific signaling pathway and/or the
particular cellular context. Clearly, additional studies are
needed to elucidate the role(s) of Cbl-b and/or Cbl in intra-
cellular signaling pathways. The current findings provide a
framework for future studies on the function of Cbl-family
proteins in TCR-mediated signal transduction, which may
be crucial for the understanding of these molecules in the
regulation of both normal and aberrant T cell responses.
Supplementary materials and methods
Antibodies
Polyclonal rabbit anti-Cbl-b (N-19 and H-121) antibodies were from
Santa Cruz Biotechnology. A polyclonal rabbit anti-Cbl-b antibody suit-
able for immunoblotting was from O. Rosnet. Anti-phosphotyrosine
monoclonal antibody 4G10 was from Upstate Biotechnology. Anti-
hemagglutinin (HA) monoclonal antibody (12CA5) was from
Boehringer Mannheim. Anti-Zap-70 monoclonal antibody was from
Transduction Lab. Anti-CD3ε monoclonal antibody, OKT3, was purified
from ascities using a protein-G—Sepharose affinity column. Horserad-
ish peroxidase-conjugated F(ab′)2 fragments of donkey anti-rabbit IgG
or sheep anti-mouse IgG were from Amersham. 
Plasmids 
The Cbl-b cDNAs encoding full-length protein (Cbl-b; amino acids
1–982), its amino-terminal region (Cbl-b(N); amino acids 1–349), a loss-
of-function mutation (G298E) of Cbl-b(N), with an HA epitope at the
carboxy-terminal end in an elongation factor promoter-driven mammalian
vector were described previously [S12,S22]. A G298E mutation in full-
length Cbl-b was made by site-directed mutagenesis (QuickChange,
Stratagene). The NFAT–luc reporter plasmid was kindly provided by G.
Crabtree. Plasmids encoding wild-type human Zap-70 or β-galactosi-
dase in pEFneo were constructed in this lab. A plasmid encoding human
Zap-70 with a Y272F mutation was from A. Chan. A dominant-negative
Ras construct (RasN17) was described previously [S10].
Cell culture, transfection, and stimulation 
Simian virus 40 T antigen (TAg)-transfected human leukemic Jurkat T
cells (Jurkat-TAg) were grown in RPMI 1640 medium (Gibco) supple-
mented with 10% fetal bovine serum and antibiotics. For protein
expression in Jurkat-TAg cells, cells were transfected with appropriate
amounts of plasmids (usually 3–10 µg total) by electroporation as pre-
viously described [S22]. For phosphotyrosine studies, cells were
resuspended (2 × 107/ml) in 0.5 ml medium, equilibrated at 37°C for
5 min, and activated with OKT3 (4 µg/ml) for 5 min. Stimulation was
terminated by adding 0.5 ml 2× Nonidet P-40 (NP-40) lysis buffer (2%
Supplementary material S3
Figure S3
Comparison of Cbl proteins with Syk in the induction of NFAT
transactivation. The experiment was performed as in Figure 1b. Cells
were also transfected with a plasmid containing Syk cDNA (5 µg) for
comparison. As shown here, Syk did not synergize with the TCR-
induced signal to induce NFAT transactivation.
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NP-40, 40 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10 mM EDTA, 10 mM
NaPiP, 10 mM NaF, 4 mM Na3VO4, 20 µg/ml each aprotinin and leu-
peptin). Cells were lysed for 10 min at 4°C and insoluble materials
were removed by centrifugation at 15,000 × g (4°C for 10 min). For
luciferase assays, cells were washed, resuspended in RPMI 1640
medium containing 0.2% FCS and incubated for 4–6 h in 24-well
plates. The cells were then left unstimulated or stimulated with either
purified OKT3 (4 µg/ml) or OKT3 ascites (1:500), ionomycin
(100 ng/ml), or PMA (50 ng/ml) for another 8–10 h. 
Immunoprecipitation and immunoblotting 
Lysates (~1 × 107 cells) were mixed with antibodies for 2 h, followed by
addition of 40 µl protein A/G Plus-Sepharose beads (Santa Cruz
Biotechnology) for an additional hour at 4°C. Immunoprecipitates were
washed four times with 1× NP-40 lysis buffer, and boiled in 20 µl 2×
Laemmli buffer. Samples were subjected to SDS/10% polyacrylamide gel
electrophoresis (PAGE) analysis and electrotransferred onto polyvinyli-
dene difluoride (PVDF) membranes (Millipore). Membranes were
immunoblotted with the indicated primary antibodies (1 µg/ml), followed
by horseradish-peroxidase-conjugated secondary antibodies. Membranes
were then washed and visualized with enhanced chemiluminescence
(ECL) detection system (Amersham). When necessary, membranes were
stripped by incubation in 62.5 mM Tris-HCl, pH 6.7/100 mM 2-mercap-
toethanol/2% SDS for 1 h at 70°C with constant agitation, washed, and
then reprobed with other antibodies as indicated. 
Luciferase assay 
The luciferase assay to determine the activation of reporter genes was
described previously [S10]. Luciferase activity was determined in tripli-
cate and expressed as arbitrary units (AU). The standard deviation
among triplicates was ≤10%, and each experiment was repeated at least
three times. As a proper control for transfection, cells were also cotrans-
fected with a pEF plasmid encoding β-galactosidase (3 µg per sample).
A portion of the cell lysates were analyzed for the enzyme activity using
o-nitrophenyl-β-D-galatopyranoside as a substrate. The relative luciferase
activity was normalized to the galactosidase enzymatic activity. 
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